Regeneron Pharmaceuticals, Inc. (LON:0R2M)

Market Cap	55.45B -10.3%
Revenue (ttm)	10.66B +1.0%
Net Income	3.35B +2.1%
EPS	30.82 +8.2%
Shares Out	n/a
PE Ratio	16.57
Forward PE	15.52
Dividend	2.68 (0.36%)
Ex-Dividend Date	Nov 20, 2025

Volume	489
Average Volume	704
Open	771.00
Previous Close	746.81
Day's Range	718.34 - 772.49
52-Week Range	477.01 - 820.00
Beta	0.39
RSI	45.99
Earnings Date	Jan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 15,222
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R2M

Financial Performance

In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.

Financial numbers in USD